Antiproliferative and Erythroid Differentiation of Piperazine and Triphenyl Derivatives Against K-562 Human Chronic Myelogenous Leukemia

Publication type:
Journal article
Metadata:
Autoren
  • Antoine Michael Saab
  • Michael Dobmeier
  • Burkhard Koenig
  • Enrica Fabri
  • Alessia Finotti
  • Monica Borgatti
  • Maria Lampronti
  • Francesco Bernardi
  • Thomas Efferth
  • Roberto Gambari
Autoren-URL
https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=fis-test-1&SrcAuth=WosAPI&KeyUT=WOS:000322559300007&DestLinkType=FullRecord&DestApp=WOS_CPL
eISSN
1791-7530
Externe Identifier
  • Clarivate Analytics Document Solution ID: 193KS
  • PubMed Identifier: 23898056
ISSN
0250-7005
Ausgabe der Veröffentlichung
8
Zeitschrift
ANTICANCER RESEARCH
Schlüsselwörter
  • Antiproliferative activity
  • piperazine derivatives
  • triphenyl derivatives
  • erythroid differentiation
  • anticancer agents
Paginierung
3027 - 3032
Datum der Veröffentlichung
2013
Status
Published
Titel
Antiproliferative and Erythroid Differentiation of Piperazine and Triphenyl Derivatives Against K-562 Human Chronic Myelogenous Leukemia
Sub types
  • Article
Ausgabe der Zeitschrift
33

Data source: Web of Science (Lite)

Other metadata sources:
Abstract
Five piperazine derivatives (S)-4-benzyl-1-(4-bromo-3-methylphenyl)-2 methylpiperazine (A), (S)-1-benzyl-3-isobutylpiperazine-2,5-dione (B), (S)-1-benzyl-3 methylpiperazine-2,5-dione (C), (S)-1,3-dibenzylpiperazine-2,5-dione (D), (E)-1-(3-methyl 4-((E)-3-(2-methylpropylidene) piperazin-1-yl) phenyl)-2-(2 methylpropylidene) piperazine (E) and triphenyl derivative ammonium 2-((2,3',3''-trimethyl-[1,1':4',1''-terphenyl]-4 yl)oxy)acetate (F) were tested for inhibition of K-562 cell proliferation and for induction of erythroid differentiation. Among them, two piperazine and one triphenyl derivatives, compounds A, E, and F inhibited the proliferation of the K562 cell lines exhibiting inhibition concentration 50 (IC50) (IC50) of values 30.10±1.6, 4.60±0.4 and 25.70±1.10 μg ml(-1), respectively. If compound A and F were added to suboptimal concentrations of the established anticancer drugs cytosine arabinoside or mithramycin, pronounced synergic effects were observed.
Addresses
  • Chemistry Department, Faculty of Sciences II, Lebanese University, Fanar, Beirut, Lebanon. antsaab@gmail.com
Autoren
  • Antoine Michael Saab
  • Michael Dobmeier
  • Burkhard Koenig
  • Enrica Fabri
  • Alessia Finotti
  • Monica Borgatti
  • Ilaria Lampronti
  • Francesco Bernardi
  • Thomas Efferth
  • Roberto Gambari
eISSN
1791-7530
Externe Identifier
  • PubMed Identifier: 23898056
Open access
false
ISSN
0250-7005
Ausgabe der Veröffentlichung
8
Zeitschrift
Anticancer research
Schlüsselwörter
  • K562 Cells
  • Erythroid Cells
  • Humans
  • Terphenyl Compounds
  • Piperazines
  • Plicamycin
  • Cell Death
  • Cell Differentiation
  • Cell Proliferation
  • Dose-Response Relationship, Drug
  • Drug Synergism
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Piperazine
Sprache
eng
Medium
Print
Paginierung
3027 - 3032
Datum der Veröffentlichung
2013
Status
Published
Datum der Datenerfassung
2013
Titel
Antiproliferative and erythroid differentiation of piperazine and triphenyl derivatives against k-562 human chronic myelogenous leukemia.
Sub types
  • Journal Article
Ausgabe der Zeitschrift
33

Data source: Europe PubMed Central

Abstract
Five piperazine derivatives (S)-4-benzyl-1-(4-bromo-3-methylphenyl)-2 methylpiperazine (A), (S)-1-benzyl-3-isobutylpiperazine-2,5-dione (B), (S)-1-benzyl-3 methylpiperazine-2,5-dione (C), (S)-1,3-dibenzylpiperazine-2,5-dione (D), (E)-1-(3-methyl 4-((E)-3-(2-methylpropylidene) piperazin-1-yl) phenyl)-2-(2 methylpropylidene) piperazine (E) and triphenyl derivative ammonium 2-((2,3',3''-trimethyl-[1,1':4',1''-terphenyl]-4 yl)oxy)acetate (F) were tested for inhibition of K-562 cell proliferation and for induction of erythroid differentiation. Among them, two piperazine and one triphenyl derivatives, compounds A, E, and F inhibited the proliferation of the K562 cell lines exhibiting inhibition concentration 50 (IC50) (IC50) of values 30.10±1.6, 4.60±0.4 and 25.70±1.10 μg ml(-1), respectively. If compound A and F were added to suboptimal concentrations of the established anticancer drugs cytosine arabinoside or mithramycin, pronounced synergic effects were observed.
Autoren
  • Antoine Michael Saab
  • Michael Dobmeier
  • Burkhard Koenig
  • Enrica Fabri
  • Alessia Finotti
  • Monica Borgatti
  • Ilaria Lampronti
  • Francesco Bernardi
  • Thomas Efferth
  • Roberto Gambari
Autoren-URL
https://www.ncbi.nlm.nih.gov/pubmed/23898056
eISSN
1791-7530
Ausgabe der Veröffentlichung
8
Zeitschrift
Anticancer Res
Schlüsselwörter
  • Antiproliferative activity
  • anticancer agents
  • erythroid differentiation
  • piperazine derivatives
  • triphenyl derivatives
  • Cell Death
  • Cell Differentiation
  • Cell Proliferation
  • Dose-Response Relationship, Drug
  • Drug Synergism
  • Erythroid Cells
  • Humans
  • K562 Cells
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Piperazine
  • Piperazines
  • Plicamycin
  • Terphenyl Compounds
Sprache
eng
Country
Greece
Paginierung
3027 - 3032
PII
33/8/3027
Datum der Veröffentlichung
2013
Status
Published
Datum, an dem der Datensatz öffentlich gemacht wurde
2013
Titel
Antiproliferative and erythroid differentiation of piperazine and triphenyl derivatives against k-562 human chronic myelogenous leukemia.
Sub types
  • Journal Article
Ausgabe der Zeitschrift
33

Data source: PubMed

Beziehungen:
Property of

Tools